Rebound effect
| Subclass of | adverse effect  |
|---|---|
| Facet give | Medication |
De rebound effect, dem sanso know as de rebound phenomenon, dey refer to de re-emergence of symptoms wey na previously be absent anaa controlled while on medication, wich dey occur wen de medication be discontinued anaa de dosage be reduced. In cases of re-emergence, de symptoms often be more severe dan dem be before treatment.
Examples
[edit | edit source]Sedative hypnotics
[edit | edit source]Stimulants
[edit | edit source]Antidepressants
[edit | edit source]Chaw antidepressants, wey dey include SSRIs, fi cause rebound depression, panic attacks, anxiety, den insomnia wen discontinued.[1]
Antipsychotics
[edit | edit source]Sudden den severe emergence[2] anaa re-emergence[3] of psychosis fi appear wen antipsychotics be switched anaa discontinued too rapidly.
Alpha-2 adrenergic agents
[edit | edit source]Rebound hypertension, above pre-treatment level, na dem observe after clonidine[4] den guanfacine[5] discontinuation.
Continuous usage of topical decongestants (nasal sprays) fi lead to constant nasal congestion, dem know as rhinitis medicamentosa.
Humanized antibodies
[edit | edit source]Oda medications
[edit | edit source]References
[edit | edit source]- ↑ Bhanji NH, Chouinard G, Kolivakis T, Margolese HC (2006). "Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena" (PDF). Can J Clin Pharmacol. 13 (1): e69–74. PMID 16456219. Archived from the original (PDF) on 2006-04-12.
- ↑ Fernandez, Hubert H.; Martha E. Trieschmann; Michael S. Okun (3 Aug 2004). "Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease". Movement Disorders. 20 (1): 104–105. doi:10.1002/mds.20260. PMID 15390047. S2CID 11574536.
- ↑ Moncrieff, Joanna (23 March 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1). John Wiley & Sons A/S: 3–13. doi:10.1111/j.1600-0447.2006.00787.x. ISSN 1600-0447. PMID 16774655. S2CID 6267180. Archived from the original on 5 January 2013. Retrieved 3 May 2009.
- ↑ Metz, Stewart; Catherine Klein; Nancy Morton (January 1987). "Rebound hypertension after discontinuation of transdermal clonidine therapy". The American Journal of Medicine. 82 (1): 17–19. doi:10.1016/0002-9343(87)90371-8. PMID 3026180. Retrieved 5 December 2012.
- ↑ Vitiello B (April 2008). "Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function". Child Adolesc Psychiatr Clin N Am. 17 (2): 459–74, xi. doi:10.1016/j.chc.2007.11.010. PMC 2408826. PMID 18295156.